New pill targets multiple KRAS mutations in Hard-to-Treat cancers
NCT ID NCT06607185
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The drug is given alone or combined with other cancer treatments to first check safety and find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY4066434 (a Pan-KRAS inhibitor drug taken by mouth)
What this could lead to
If this drug is safe and shows promise, it could lead to a new treatment option for several cancers driven by KRAS mutations, such as pancreatic, lung, and colorectal cancer.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if the drug will work. Side effects are unknown, and the drug may not shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asklepios Kliniken Hamburg GmbH - Asklepios Klinik Altona
Hamburg, 22763, Germany
-
Cancer Institute Hospital of JFCR
Tokyo, 135-8550, Japan
-
Centre Leon Berard
Lyon, 69373, France
-
Centro Ricerche Cliniche di Verona s.r.l.
Verona, 37134, Italy
-
City of Hope
Duarte, California, 91010, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Cliniques universitaires Saint-Luc
Brussels, 1200, Belgium
-
Columbia University
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hospital General Universitario Gregorio Maranon
Madrid, 28007, Spain
-
Hospital Regional Universitario de Malaga
Málaga, 29010, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital del Mar
Barcelona, 08003, Spain
-
Indiana University (IU)
Indianapolis, Indiana, 46202, United States
-
Institut Catala d'Oncologia - L'Hospitalet
Barcelona, 08908, Spain
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Krankenhaus Nordwest GmbH
Frankfurt, 60488, Germany
-
Kyoto University Hospital
Kyoto, 606-8507, Japan
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
National Cancer Center Hospital
Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Chiba, 277-8577, Japan
-
National Taiwan University Hospital
Taipei, 10016, Taiwan
-
National Taiwan University Hospital Hsin-Chu Branch
Hsinchu, 300195, Taiwan
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
SLK-Kliniken Heilbronn GmBH
Heilbronn, 74078, Germany
-
Sarah Cannon Research Institute/SCRI
Nashville, Tennessee, 37203, United States
-
Shizuoka Cancer Center
Shizuoka, 411-8777, Japan
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, Michigan, 49546, United States
-
Swedish Cancer Institute (SCI)
Seattle, Washington, 98104, United States
-
The University of Chicago Medical Center (UCMC)
Chicago, Illinois, 60637, United States
-
UZ Gent
Ghent, 9000, Belgium
-
Universitaetsklinikum Wuerzburg
Würzburg, 97080, Germany
-
Universite Libre de Bruxelles (ULB) - Institut Jules Bordet
Brussels, 1070, Belgium
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of California, Los Angeles (UCLA)
Santa Monica, California, 90404, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of Texas Southwestern
Dallas, Texas, 75244, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
-
Yale University School of Medicine - Yale Cancer Center
New Haven, Connecticut, 06520-8028, United States